SCHOFIELD, Wis., June 1, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic™, announced today that it has signed a $5 million purchase agreement with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.
